Julie Suman and Nektaria Karavas discuss the challenges and opportunities of intranasal vaccination – showcasing current understanding for both liquid and powder products. Experimental studies highlight critical issues, the performance of commercially available devices and developments in formulation practice.
NASAL DELIVERY SYSTEM EXPANDS PUBLIC AND PATIENT ACCESS TO NALOXONE TO MITIGATE THE OPIOID OVERDOSE EPIDEMIC
Christophe Marie, Taylor Price and Julien Storz chart the commitments and progress made to date by Aptar in achieving its sustainability targets. The authors also provide examples of integrated, circular economy initiatives undertaken by Aptar Pharma at a product solution level and comment on concrete commitments that can be made to further progress towards sustainability.
Richard Johnson discusses the advantages of nasal delivery and why there is growing interest in this route of administration, as well as considering some of the challenges that may arise during the development of nasal formulations for use in the clinic, and the regulatory and testing requirements associated with them.
In this exclusive interview with ONdrugDelivery, Aaron Mann discusses how Kindeva is positioned to move forward as a major CDMO specialising in inhalation and transdermal dosage forms, having been formed from 3M’s drug delivery in May 2020. We also cover the impact of Covid-19, environmental sustainability, and current challenges faced by the pharmaceutical industry.